Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Rossi, M. Shimizu, E. Barbarotto, M. Nicoloso, Federica Dimitri, D. Sampath, M. Fabbri, S. Lerner, Lynn Barron, L. Rassenti, Li Jiang, Lianchun Xiao, Jianhua Hu, P. Secchiero, G. Zauli, S. Volinia, M. Negrini, W. Wierda, T. Kipps, W. Plunkett, K. Coombes, L. Abruzzo, M. Keating, G. Calin (2010)microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
Blood, 116 6
D. Rossi, S. Rasi, G. Fabbri, V. Spina, M. Fangazio, F. Forconi, R. Marasca, L. Laurenti, A. Bruscaggin, M. Cerri, S. Monti, S. Cresta, R. Famà, L. Paoli, P. Bulian, V. Gattei, A. Guarini, S. Deaglio, D. Capello, R. Rabadán, L. Pasqualucci, R. Dalla-Favera, R. Foà, G. Gaidano (2012)Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
Blood, 119 2
M. Nishio, T. Endo, N. Tsukada, J. Ohata, S. Kitada, John Reed, N. Zvaifler, T. Kipps (2005)Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.
Blood, 106 3
Raphael Kopan, M. Ilagan (2004)γ-Secretase: proteasome of the membrane?
Nature Reviews Molecular Cell Biology, 5
Michael Ghermezi, Mingjie Li, S. Vardanyan, N. Harutyunyan, J. Gottlieb, A. Berenson, T. Spektor, C. Andreu-Vieyra, S. Petraki, Eric Sanchez, Kyle Udd, Cathy Wang, R. Swift, Haiming Chen, J. Berenson (2016)Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
N. Pflug, J. Bahlo, T. Shanafelt, B. Eichhorst, M. Bergmann, T. Elter, Kathrin Bauer, G. Malchau, K. Rabe, S. Stilgenbauer, H. Döhner, U. Jäger, M. Eckart, G. Hopfinger, R. Busch, A. Fink, C. Wendtner, K. Fischer, N. Kay, M. Hallek (2014)Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
Blood, 124 1
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, M. Thun (2007)Cancer Statistics, 2007
CA: A Cancer Journal for Clinicians, 57
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, N. Chiorazzi, S. Stilgenbauer, K. Rai, J. Byrd, B. Eichhorst, S. O'brien, T. Robak, J. Seymour, T. Kipps (2018)iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Blood, 131 25
R Kopan, MX Ilagan (2004)Gamma-secretase: proteasome of the membrane?
Nat Rev Mol Cell Biol, 5
T. Endo, M. Nishio, T. Enzler, H. Cottam, T. Fukuda, D. James, M. Karin, T. Kipps (2007)BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Blood, 109 2
Sarah Laurent, Franziska Hoffmann, P. Kuhn, Q. Cheng, Yuanyuan Chu, Marc Schmidt-Supprian, Stefanie Hauck, Elisabeth Schuh, M. Krumbholz, Heike Rübsamen, Johanna Wanngren, M. Khademi, Tomas Olsson, Tobias Alexander, F. Hiepe, Hans-Walter Pfister, Frank Weber, Dieter Jenne, H. Wekerle, Reinhard Hohlfeld, S. Lichtenthaler, E. Meinl (2015)γ-secretase directly sheds the survival receptor BCMA from plasma cells
Nature Communications, 6
T. Hamblin, Z. Davis, A. Gardiner, D. Oscier, F. Stevenson (1999)Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
D. Rossi, M. Fangazio, S. Rasi, T. Vaisitti, S. Monti, S. Cresta, S. Chiaretti, I. Giudice, G. Fabbri, A. Bruscaggin, V. Spina, C. Deambrogi, M. Marinelli, R. Famà, M. Greco, G. Daniele, F. Forconi, V. Gattei, F. Bertoni, S. Deaglio, L. Pasqualucci, A. Guarini, R. Dalla-Favera, R. Foà, G. Gaidano (2011)Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Blood, 119 12
Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy Wang, Dylan Kirk, O. Yellin, C. Nichols, M. Dreyer, Cameryn Ahles, Austin Robinson, E. Madden, G. Waterman, R. Swift, B. Bonavida, R. Boccia, R. Vescio, J. Crowley, Haiming Chen, J. Berenson (2012)Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
British Journal of Haematology, 158
A. Novak, J. Darce, B. Arendt, B. Harder, K. Henderson, W. Kindsvogel, J. Gross, P. Greipp, D. Jelinek (2004)Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Blood, 103 2
H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, Martin Bentz, P. Lichter (2000)Genomic aberrations and survival in chronic lymphocytic leukemia.
The New England journal of medicine, 343 26
T. Hamblin, Z. Davis, A. Gardiner, D. Oscier, F. Stevenson (1999)Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood, 94 6
R. Guièze, P. Robbe, R. Clifford, S. Guibert, Bruno Pereira, A. Timbs, M. Dilhuydy, M. Cabes, L. Ysebaert, A. Burns, F. Nguyen‐Khac, F. Davi, L. Véronèse, P. Combes, M. Garff-Tavernier, V. Leblond, H. Merle-Béral, R. Alsolami, A. Hamblin, J. Mason, A. Pettitt, P. Hillmen, Jenny Taylor, S. Knight, O. Tournilhac, A. Schuh (2015)Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Blood, 126 18
Kyle Crassini, E. Zhang, Shalini Balendran, J. Freeman, O. Best, Cecily Forsyth, Naomi Mackinlay, P. Han, William Stevenson, Stephen Mulligan (2018)Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment‐free and overall survival in Chronic Lymphocytic Leukaemia
British Journal of Haematology, 181
W. Wierda, S. O'brien, Xuemei Wang, S. Faderl, A. Ferrajoli, K. Do, G. Garcia-Manero, J. Cortes, D. Thomas, C. Koller, J. Burger, S. Lerner, H. Kantarjian, M. Keating (2009)Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 10
Background Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes. Objective We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL. Patients and Methods Using an enzyme-linked immunosorbent assay (ELISA), we assessed plasma (p) levels of BCMA in 171 CLL patients and compared them with levels in healthy individuals. Results pBCMA levels were significantly higher among patients with CLL than those from healthy donors (p < 0.0001). Among patients with aggressive disease, pBCMA was elevated compared with patients with indolent disease (p < 0.001). Those with an initial pBCMA level in the highest quartile had a shorter time to first treatment compared with CLL patients with pBCMA levels in the lowest three quartiles (p < 0.0001). Among those in the highest quartile (pBCMA > 110.9 ng/ mL), overall survival was shorter than those in the lowest three quartiles (p = 0.0007). Finally, among those patients who underwent serial pBCMA testing, changes in these levels correlated with changes in their clinical status. Conclusions Together, our findings show that pBCMA is a promising new
Targeted Oncology – Springer Journals
Published: Aug 31, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.